emerg
viral
pathogen
includ
newli
discov
virus
well
previous
known
virus
either
increas
threaten
increas
incid
often
first
identifi
gener
popul
may
affect
transplant
recipi
manifest
may
atyp
sever
enhanc
molecular
method
increas
rate
viral
discoveri
overcom
problem
demonstr
pathogen
time
improv
clinic
diagnost
method
increas
detect
reemerg
virus
immunocompromis
patient
review
first
discuss
viral
diagnost
develop
field
viral
discoveri
focu
rare
emerg
virus
transplant
popul
human
tcell
leukemia
viru
type
hepat
e
viru
bocaviru
ki
wu
polyomavirus
coronavirus
influenza
measl
dengu
rabi
lymphocyt
choriomening
viru
detect
report
rare
pathogen
transplant
recipi
critic
patient
care
improv
understand
posttranspl
infect
emerg
infecti
diseas
caus
pathogen
newli
recogn
whose
incid
either
increas
preced
decad
threaten
increas
viral
diseas
account
larg
proport
infect
context
transplant
recipi
import
emerg
virus
consid
type
novel
virus
known
virus
increas
incid
gener
popul
potenti
transplant
recipi
previous
known
virus
caus
diseas
increas
sever
immunocompromis
host
review
begin
discuss
viral
diagnost
evolv
field
viral
discoveri
increas
speed
viru
identif
creat
new
challeng
focu
shift
specif
emerg
reemerg
viral
pathogen
transplant
commun
virus
describ
case
seri
multipl
case
report
list
tabl
virus
describ
singl
case
report
list
tabl
potenti
risk
viral
transmiss
result
xenotransplant
address
viral
discoveri
typic
reli
abil
detect
new
virus
cell
cultur
although
clinic
virolog
laboratori
affili
transplant
center
routin
perform
viral
cultur
mani
pathogen
grow
well
grow
viral
detect
use
cultur
limit
number
cell
line
laboratori
realist
maintain
pathogen
detect
clinic
laboratori
also
limit
avail
test
often
target
conserv
sequenc
polymeras
chain
reaction
pcr
realtim
rt
pcr
specif
antigen
antibodi
detect
known
virus
multiplex
test
clinic
syndrom
particularli
respiratorytract
infect
allow
less
bias
approach
viral
diagnosi
still
face
limit
identifi
emerg
pathogen
rare
situat
unusu
viru
may
detect
test
known
pathogen
case
woman
present
usutu
viremia
gave
lowposit
result
west
nile
viru
rtpcr
number
rapid
molecular
method
employ
viral
discoveri
categor
sequenc
depend
panvir
microarray
sequenceindepend
techniqu
panvir
microarray
array
spot
oligonucleotid
sequenc
repres
known
viral
pathogen
novel
virus
identifi
suffici
similar
exist
sequenc
new
viru
array
amplicon
recov
array
clone
sequenc
technolog
use
identif
sar
coronaviru
cultur
patient
isol
pcr
base
conserv
sequenc
gener
limit
applic
viral
diagnost
virus
contain
highli
conserv
sequenc
analog
ribosom
rna
sequenc
util
bacteri
identif
sequenceindepend
amplif
sequenc
viral
nucleic
acid
biolog
sampl
term
viral
metagenom
sequenceindepend
approach
includ
subtract
hybrid
represent
differ
analysi
sequenceindepend
singleprim
amplif
roll
circl
amplif
techniqu
use
identifi
agent
human
herp
viru
torqu
teno
virus
ttv
hepat
e
viru
hev
norwalk
viru
parvoviru
human
bocaviru
hbov
viral
metagenom
aid
develop
number
new
sequenc
platform
term
nextgener
sequenc
ng
deepsequenc
technolog
allow
rapid
parallel
gener
sequenc
per
run
current
technolog
reli
nonspecif
amplif
viral
dna
rna
sampl
treat
remov
host
nucleic
acid
amplif
follow
sequenc
synthesi
use
differ
technolog
detect
base
incorpor
ng
util
identifi
novel
virus
patient
sampl
studi
fever
unknown
origin
ng
great
abil
detect
known
previous
unknown
diverg
virus
mere
detect
demonstr
causat
mani
virus
classic
koch
postul
appli
demonstr
ttv
hbov
establish
caus
role
agent
difficult
mokili
colleagu
propos
metagenom
koch
postul
whether
suffici
remain
moot
time
ng
larg
tool
research
purpos
sequenc
reaction
take
good
deal
time
set
perform
run
gener
massiv
amount
data
must
filter
prior
analysi
use
variou
align
program
design
handl
larg
number
short
read
final
result
must
interpret
care
contamin
laboratori
even
commerci
reagent
often
identifi
eg
xenotrop
murin
leukemia
virusrel
viru
confirm
presenc
viru
identifi
small
number
read
may
possibl
human
tcell
leukemia
viru
type
human
tcell
leukemia
viru
type
seropreval
rate
rang
endem
area
western
countri
chronic
infect
associ
adult
tcell
leukemia
atl
myelopathi
ham
fewer
infect
concern
immunosuppress
transplant
recipi
may
trigger
progress
complic
yoshizumi
et
al
identifi
live
donor
liver
transplant
recipi
atl
develop
patient
day
post
transplant
patient
die
includ
atl
overal
surviv
rate
differ
recipi
liver
transplant
recipi
institut
case
report
atl
follow
renal
transplant
patient
document
though
case
seri
renal
transplant
recipi
total
patient
year
followup
case
atl
ham
develop
ham
report
dr
livingrel
liver
transplant
recipi
atl
respond
poorli
convent
chemotherapi
highest
median
surviv
rate
report
clinic
trial
approxim
month
consequ
hematopoiet
stem
cell
transplant
hsct
evalu
treatment
atl
patient
hsct
use
describ
transplant
multipot
stem
cell
bone
marrow
peripher
cord
blood
largest
studi
hsct
atl
involv
retrospect
analysi
patient
atl
undergon
allogen
hsct
center
japan
surviv
rate
atl
recur
patient
surviv
day
post
transplant
receiv
transplant
relat
seroposit
donor
higher
risk
diseaseassoci
mortal
rel
whose
relat
donor
neg
hsct
recipi
complet
remiss
time
transplant
higher
rate
surviv
compar
patient
complet
remiss
vs
transmiss
transplant
transfus
document
spain
recipi
organ
singl
donor
liver
kidney
transplant
develop
ham
within
year
transplant
two
case
report
document
occurr
ham
heart
transplant
recipi
hsct
recipi
acquir
blood
transfus
lowpreval
area
howev
univers
donor
screen
enzymelink
immunosorb
assay
follow
western
blot
result
mani
fals
posit
practic
longer
recommend
unit
state
organ
procur
transplant
network
hev
common
caus
acut
liver
diseas
develop
world
primarili
fecalor
spread
contamin
drink
water
infect
develop
nation
well
describ
typic
result
consumpt
undercook
pork
product
immunocompet
host
hev
acut
infect
selflimit
rare
progress
fulmin
liver
failur
howev
immunosuppress
host
chronic
infect
mark
persist
viremia
abnorm
liver
function
eventu
progress
cirrhosi
occur
case
describ
recipi
varieti
transplant
includ
kidney
liver
heart
lung
multicent
review
case
acut
hev
infect
solid
organ
transplant
sot
recipi
develop
chronic
hepat
develop
cirrhosi
use
tacrolimu
compar
cyclosporin
independ
predictor
chronic
infect
rare
case
enceph
polyradiculopathi
hev
rna
detect
cerebrospin
fluid
csf
also
describ
major
hev
infect
follow
sot
result
de
novo
infect
unlik
repres
viru
reactiv
rare
instanc
transmiss
blood
transfus
donat
graft
report
determin
overal
incid
hevrel
diseas
follow
transplant
hamper
avail
diagnost
test
none
food
drug
administr
fda
approv
commerci
serolog
assay
variabl
test
characterist
test
hev
rna
detect
serum
stool
sampl
routin
avail
report
hev
infect
follow
hsct
limit
individu
case
hev
reactiv
follow
hsct
report
review
antihev
immunoglobin
gposit
patient
prior
hsct
show
evid
diseas
reactiv
treatment
prolong
hev
viremia
often
involv
reduc
immunosuppress
pegyl
interferon
administr
shown
induc
sustain
virolog
respons
limit
group
patient
approach
viral
control
may
increas
risk
graft
reject
ribavirin
monotherapi
induc
sustain
virolog
respons
without
risk
reject
may
repres
firstlin
agent
treatment
clinic
relev
nonsar
human
coronavirus
hcov
identifi
last
decad
middl
east
respiratori
syndrom
hcov
merscov
identifi
prospect
studi
found
hcov
infect
asymptomat
none
infect
allogen
hsct
recipi
develop
lowerrespiratorytract
infect
although
prolong
viral
excret
frequent
nonetheless
report
fatal
hcov
infect
follow
hsct
evid
among
sot
recipi
hcov
caus
sever
lowerrespiratorytract
infect
increas
risk
graft
reject
appear
virul
previous
discov
howev
recent
identifi
merscov
associ
sever
pneumonia
high
mortal
rate
case
yet
involv
immunocompromis
host
effort
identifi
novel
respiratori
pathogen
led
discoveri
hbov
ki
wu
polyomavirus
kipyv
wupyv
virus
detect
patient
respiratori
symptom
evid
support
caus
role
agent
sever
diseas
lack
studi
evalu
hbov
respiratori
pathogen
immunocompromis
adult
detect
viru
infrequ
document
effect
patient
outcom
establish
hbov
respiratori
pathogen
also
complic
high
rate
copathogen
detect
hbov
detect
asymptomat
patient
viral
dissemin
transplant
recipi
occur
hbov
detect
blood
stool
howev
patient
often
hbov
detect
week
hospit
pathogen
also
detect
episod
commerci
platform
multiplex
detect
respiratori
pathogen
includ
hbov
specif
antivir
treatment
avail
kipyv
wupyv
detect
nasopharyng
bronchoalveolar
lavag
sampl
sot
hsct
recipi
detect
virus
associ
sputum
product
wheez
follow
hsct
howev
similar
hbov
virus
often
codetect
pathogen
associ
sever
respiratori
tract
diseas
mortal
immunocompromis
host
suscept
complic
influenza
howev
clear
emerg
strain
necessarili
caus
sever
diseas
one
case
seri
sot
patient
influenza
show
requir
icu
admiss
die
seri
among
hsct
recipi
show
similar
find
comparison
outcom
kidney
transplant
immunocompet
patient
differ
morbid
mortal
date
case
influenza
report
transplant
recipi
recent
rise
measl
incid
bring
consider
signific
manifest
may
subacut
measl
enceph
sme
though
sever
case
pneumonia
document
sme
develop
renal
transplant
recipi
singl
hsct
recipi
patient
may
present
measlescompat
ill
improv
develop
alter
mental
statu
seizur
week
later
fever
uncommon
first
imag
chang
seen
magnet
reson
imag
diagnosi
confirm
immunoglobin
igm
seroconvers
rtpcr
clinic
cours
one
deterior
mental
statu
treatmentrefractori
seizur
four
transplant
case
sme
die
survivor
signific
neurolog
deficit
incid
measl
transplant
recipi
well
proport
sever
diseas
unclear
two
seri
identifi
case
interstiti
pneumonia
fatal
among
hsct
recipi
diagnos
measl
though
methodolog
limit
exist
studi
dengu
viru
denv
common
vectorborn
viral
diseas
worldwid
detect
increas
number
countri
last
year
case
seri
involv
renal
transplant
recipi
singl
case
sever
dengu
develop
fatal
loss
graft
function
sever
case
dengu
includ
death
report
renal
transplant
recipi
along
fatal
case
liver
transplant
recipi
hsct
recipi
patient
die
diseas
typic
develop
within
first
month
post
transplant
humantohuman
transmiss
denv
result
sot
hsct
postul
transfusionrel
denv
infect
report
fdaapprov
diagnost
includ
test
igm
detect
center
diseas
control
preventiondevelop
rtpcr
manag
consist
support
care
seventeen
case
rabi
report
transplant
recipi
date
transmit
transplant
tissu
organ
nine
case
follow
corneal
transplant
includ
death
sole
survivor
report
began
postexposur
prophylaxi
pep
postop
day
two
cluster
texa
germani
total
rabi
case
occur
follow
sot
case
follow
transplant
liver
lung
kidney
kidneypancrea
iliac
arteri
graft
patient
typic
develop
enceph
day
post
transplant
symptomat
patient
die
patient
germani
receiv
pep
antivir
treatment
though
postop
day
liver
recipi
cluster
previous
vaccin
never
develop
diseas
donor
later
determin
rabi
exposur
bat
dog
bite
respect
recent
report
maryland
document
fatal
case
rabi
develop
year
kidney
transplant
transmiss
raccoonvari
rabi
donat
graft
confirm
three
graft
recipi
donor
aliv
though
full
detail
avail
manag
rabi
focus
prevent
vaccin
highrisk
patient
pep
transplant
recipi
receiv
pep
mount
adequ
respons
antibodi
titer
intern
unitsml
though
titer
lower
immunocompet
patient
base
experi
german
liver
transplant
recipi
rabi
vaccin
may
remain
effect
even
transplant
case
lymphocyt
choriomening
viru
lcmv
transmit
organ
transplant
cluster
includ
case
death
document
abil
pathogen
caus
sever
diseas
immunocompromis
host
anoth
cluster
involv
transmiss
relat
arenaviru
australia
similar
outcom
liver
kidney
recipi
death
rabi
infect
post
transplant
case
result
transmiss
organ
transplant
time
case
describ
hsct
popul
case
cluster
lcmv
infect
occur
unit
state
involv
kidney
liver
lung
transplant
symptom
develop
day
post
transplant
includ
fever
abdomin
pain
nausea
diarrhea
alter
mental
statu
patient
often
develop
periincision
rash
tender
csf
find
includ
elev
protein
often
mark
normal
low
glucos
mild
pleocytosi
three
patient
surviv
lcmv
infect
follow
sot
kidney
recipi
liver
recipi
ribavirin
employ
case
though
benefit
remain
unclear
three
corneal
transplant
recipi
potenti
expos
lcmv
though
none
develop
symptom
seroconvert
contact
investig
reveal
exposur
rodent
posit
test
lcmv
donor
investig
fourth
donor
reveal
exposur
test
perform
remain
tissu
neg
advis
immunocompromis
patient
avoid
contact
rodent
includ
pet
though
mode
lcmv
acquisit
outbreak
major
viral
infect
discuss
data
insuffici
determin
true
incid
diseas
transplant
recipi
measl
mump
yellow
fever
vaccineprevent
ill
though
vaccin
liveattenu
recommend
follow
transplant
also
antibodi
respons
vaccin
less
immunocompet
patient
donortransmit
rabi
carri
dire
prognosi
though
limit
data
exist
use
pep
transplant
recipi
appear
safe
given
appar
rariti
screen
mani
diseas
organ
donor
recommend
exampl
discuss
earlier
lcmv
illustr
difficulti
involv
donor
screen
outbreak
investig
lcmv
donor
detect
antibodi
inde
rtpcr
multipl
sampl
fail
detect
lcmv
donor
yield
posit
result
singl
lymph
node
anoth
seem
prudent
obtain
comprehens
histori
potenti
organ
donor
though
remain
unclear
certain
find
rodent
ownership
affect
one
donor
statu
report
rare
infect
transplant
recipi
help
identifi
agent
research
need
screen
may
warrant
howev
like
infect
underdiagnos
symptom
may
attribut
common
potenti
coincid
posttranspl
infect
